With tariffs on patented pharmaceuticals and input materials set to take effect for all companies on Sept. 29, the lack of clarity about rules […]
With pharmaceutical tariffs looming, guidance on compliance is still lacking Read More »
Stronger intellectual property protection statistically correlates with increased development of cutting-edge therapies and greater investment in life sciences research, according to a closely watched
Strong IP ecosystems drive biotech R&D and investment, report shows Read More »
“Context around patient-identified affordability and access challenges is really critical,” began Karin Hoelzer, DVM, PhD, Senior Director, Patient Advocacy during the Biotechnology Innovation Organization’s
Affordability and Access: Why patient perspectives matter Read More »
For years, advocates have pushed for more research and investment in women’s health. Now, it may be paying off. “I’m excited about the medicine
BIO 2026: Are we entering the ‘golden era’ of women’s health? Read More »
A Food and Drug Administration (FDA) pilot program to expedite approval of new drugs contains potentially impactful initiatives but risks adding burdens, says the
BIO applauds efforts targeting early drug development efficiency, provides suggestions Read More »
An agreement designed to shape the future of drug approval recommends new efficiencies while leaning into the existing strengths of a system that makes
PDUFA letter stresses stability, transparency, maturity, says BIO negotiator Read More »
Generative genomics uses AI to analyze genetic sequences for innovative treatments. Every industry is racing to optimize AI in their operations. For many biotech
BIO 2026: Generative genomics helps biotechs design better, not just faster Read More »
For people living with psoriatic disease, treatment innovation has advanced dramatically. Yet too many patients remain undiagnosed, untreated, or undertreated. The National Psoriasis Foundation
Connecting more patients with psoriasis to the care they need Read More »
BIO’s response to a request for information from the Drug Price Working Group explains why price setting won’t work. Improving patient access to new
Build patient access by strengthening innovation, BIO tells senators Read More »
2026 was a busy year on the state level. Whether it was the expected healthcare policy priorities or newer ones, there was plenty to
Mid-year review: State-level legislative action impacting biotech Read More »
